Regeneron Pharmaceuticals (REGN) News Today $681.58 -11.65 (-1.68%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 20 at 4:00 PM | prnewswire.comRegeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value ...January 20 at 3:31 PM | gurufocus.comRegeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens BermanJanuary 20 at 2:56 PM | globenewswire.comREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. ...January 20 at 11:42 AM | gurufocus.comREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 20 at 10:55 AM | prnewswire.comREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud LawsuitJanuary 20 at 9:00 AM | prnewswire.comCove Private Wealth LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Cove Private Wealth LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 440 shares of the biopharmaceutical company's stockJanuary 20 at 8:53 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of ...January 20 at 6:08 AM | gurufocus.comRegeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNJanuary 20 at 5:45 AM | prnewswire.comREGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 19 at 4:28 PM | investing.comROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. ...January 19 at 12:32 PM | gurufocus.comROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGNJanuary 19 at 11:13 AM | globenewswire.comJim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’January 19 at 8:07 AM | insidermonkey.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Moss Adams Wealth Advisors LLCMoss Adams Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 212.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,357 shares of the biopharmaceutical company'January 19 at 6:42 AM | marketbeat.comMonarch Capital Management Inc. Acquires 549 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Monarch Capital Management Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 106.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,067 shares of the biopharmJanuary 19 at 6:42 AM | marketbeat.comROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGNJanuary 18 at 1:55 PM | investing.comREGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitJanuary 18 at 8:55 AM | globenewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron PharmaceuticalsJanuary 18 at 8:18 AM | investing.comB & T Capital Management DBA Alpha Capital Management Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)B & T Capital Management DBA Alpha Capital Management increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 154.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,1January 18 at 7:52 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Procyon Advisors LLCProcyon Advisors LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,481 shares of the biopharmaceutical company'sJanuary 18 at 5:26 AM | marketbeat.comWhat to Expect From Regeneron Pharmaceuticals's Q4 2024 Earnings ReportJanuary 18 at 12:07 AM | msn.comRobbins LLP Urges REGN Stockholders with Large Losses to Contact the Firm for Information About the Class Action Against Regeneron Pharmaceuticals, IncJanuary 17, 2025 | globenewswire.comRegeneron Pharmaceuticals Faces Securities Class Action LawsuitJanuary 17, 2025 | gurufocus.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGNJanuary 17, 2025 | investing.comRegeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens BermanJanuary 17, 2025 | globenewswire.comRegeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJanuary 17, 2025 | prnewswire.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Boston Common Asset Management LLCBoston Common Asset Management LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,818 shares of the biopharmaceutical company's stock after selling 7,258 shareJanuary 17, 2025 | marketbeat.comAvanza Fonder AB Makes New $7.41 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Avanza Fonder AB bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,408 shares of the biopharmaceutical comJanuary 17, 2025 | marketbeat.comWoodstock Corp Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Woodstock Corp reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,655 shares of the biopharJanuary 17, 2025 | marketbeat.comNASDAQ: REGN INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a March 10, 2025 DeadlineJanuary 17, 2025 | globenewswire.comRegeneron Pharmaceuticals Faces Class Action Lawsuit Over Alleged Securities FraudJanuary 17, 2025 | gurufocus.comShareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGNJanuary 17, 2025 | prnewswire.comOutlook Wealth Advisors LLC Invests $305,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Outlook Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 428 shares of the biopharmaceutical company's stock, valued at approximatelJanuary 17, 2025 | marketbeat.comFifth Third Wealth Advisors LLC Has $783,000 Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Fifth Third Wealth Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 118.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,099 shares of the biopharmJanuary 17, 2025 | marketbeat.comUBS Downgrades Regeneron Pharmaceuticals (REGN)January 17, 2025 | msn.comROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGNJanuary 16, 2025 | globenewswire.comWhat to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings ReportJanuary 16, 2025 | msn.comREGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 16, 2025 | globenewswire.comRegeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – REGNJanuary 16, 2025 | globenewswire.comUBS cuts rating on Regeneron stock amid Eylea uncertaintyJanuary 16, 2025 | msn.comREGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 16, 2025 | prnewswire.comRegeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Neutral at UBS GroupUBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the company from $1,130.00 to $738.00 in a research report on Thursday.January 16, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Connective Portfolio Management LLCConnective Portfolio Management LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 97.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 630 sharesJanuary 16, 2025 | marketbeat.comThe Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNJanuary 16, 2025 | prnewswire.comRegeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens BermanJanuary 15, 2025 | globenewswire.comREGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud LawsuitJanuary 15, 2025 | prnewswire.comThe Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – REGNJanuary 15, 2025 | globenewswire.comJim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’January 15, 2025 | insidermonkey.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron PharmaceuticalsJanuary 15, 2025 | prnewswire.comRegeneron: Phase III Success In Skin Cancer For LibtayoJanuary 15, 2025 | seekingalpha.com Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Media Mentions By Week REGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.240.46▲Average Medical News Sentiment REGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼6419▲REGN Articles Average Week Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amgen News Gilead Sciences News Vertex Pharmaceuticals News Alnylam Pharmaceuticals News Biogen News United Therapeutics News Neurocrine Biosciences News Incyte News BioMarin Pharmaceutical News Exelixis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REGN Stock Alerts